Roche Diagnostics K.K. is the Japanese diagnostics subsidiary of the Roche Group, operating as a kabushiki kaisha (K.K.) and serving hospitals, clinical laboratories, and research institutions across Japan. The company markets, supplies, and supports in vitro diagnostic systems, reagents, and related software, and provides technical service and training for installed platforms.
Its portfolio spans immunoassay and clinical chemistry analyzers, molecular diagnostics (including PCR-based testing), tissue diagnostics, and point-of-care solutions. Roche Diagnostics K.K. also collaborates with pharmaceutical partners on companion diagnostics that help determine patient eligibility for specific therapies, supporting personalized healthcare and compliance with Japanese regulatory and reimbursement requirements.
None yet. When a new project in the record names Roche Diagnostics K.K. as owner, partner or investor, it shows here.
ELEVIDYS, a one-time therapy for DMD, targets ambulatory patients aged 3-7. Safety measures and post-marketing studies are in place following reports of liver failure cases.
